ArticleFrontiers in immunology2026

CMTM6/PD-L1-targeted AAV promotes anti-tumor immune responses and chemotherapy responsiveness.

Runqiu Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.